Roche customers will now have even more opportunities to utilise ResistancePlus® tests to support clinically important treatment decisions. SpeeDx ResistancePlus® MG and ResistancePlus® GC are now validated for cobas z...
SpeeDx have partnered with researchers from Nepean Hospital in an exclusive agreement to commercialise a molecular test for IFI27 - a host biomarker with expression strongly correlated with disease progression...
SpeeDx in partnership with Nepean Blue Mountains Local Health District’s (NBMLHD) Nepean Hospital Intensive Care Unit were awarded funding through the MTPConnect Biomedical Translation Bridge (BTB) program. Funds will support...
The pandemic environment of COVID-19 has shined a spotlight on the importance of clinical diagnostics. Now, more than ever, the growth and success of SpeeDx has global reach in terms...
SpeeDx has partnered with Roche, a global pioneer in pharmaceuticals and diagnostics, to expand access to infectious disease and antibiotic resistance tests and technology. Under the terms of the agreement,...
SpeeDx and LabCorp are working together to develop and introduce new tests with the promise to help improve patient care, focusing on women’s health and infectious diseases. "We are excited about...
The Foundation for Innovative New Diagnostics (FIND) are supporting a collaboration with SpeeDx and QuantuMDx to assess the feasibility of developing low-cost point of care (POC) tests for common sexually...
The Therapeutic Goods Administration (TGA) have cleared ResistancePlus® MG FleXible for the Cepheid GeneXpert® System, and it is now available for sale in Australia. This announcement further expands access to...
ResistancePlus® MG FleXible for the Cepheid GeneXpert® System is now CE-IVD and available for sale in Europe. The test detects the sexually transmitted infection (STI) Mycoplasma genitalium (Mgen) and markers...
Researchers at The University of Western Australia and King Edward Memorial Hospital have teamed up with SpeeDx to commercialise a new low-cost test to identify women at risk of premature...